亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Bioreversible Phosphotriester Rnai-Inducing Molecules

詳細技術說明: RNAi responses have great potential to treat human disease, especially cancer and viral infections. However, siRNAs are macromolecules with no bioavailability to enter cells and require a delivery agent. Here we developed RNAi-molecules delivered into cells by the TAT Peptide Transduction Domain (PTD) peptide. Although we have only performed cell culture experiments, the technology holds promise for eventual development of RNAi therapeutics.

*Principal Investigation: Name: Steven Dowdy
Department:

Name: Khirud Gogoi
Department:

Name: Bryan Meade
Department:

附加資料: Inventor: DOWDY, Steven F. | MEADE, Bryan R. | GOGOI, Khirud
Priority Number: WO2014031575A1
IPC Current: C07H002100 | C12N001511
Assignee Applicant: The Regents of the University of California
Title: POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | POLYNUCLÉOTIDES POSSÉDANT DES GROUPES BIORÉVERSIBLES
Usefulness: POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | POLYNUCLÉOTIDES POSSÉDANT DES GROUPES BIORÉVERSIBLES
Summary: The polynucleotide construct is useful: for reducing the expression of a protein in a cell via by reducing gene expression (claimed); and as therapeutics for treating disorders such as cancer (leukemia or myelodysplastic syndrome) in humans, and as diagnostics and tools for research. Test details are described but no results given.
Novelty: New polynucleotide construct comprising first component (e.g. peptide and therapeutic agent) linked to it through bioreversible group attached to internucleotide bridging group, used e.g. to reduce protein expression and treat cancer

欲了解更多信息，請點擊這裡